Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dCas9-HDAC2 is an epigenome editing tool consisting of a catalytically inactive Cas9 (dCas9) protein fused to the histone deacetylase 2 (HDAC2) enzyme. This chimeric protein is directed to specific genomic sequences by a guide RNA (gRNA). Once bound to the target promoter or enhancer, the HDAC2 domain removes acetyl groups from lysine residues on histone tails (such as H3K27ac), leading to chromatin condensation and transcriptional repression of the target gene. This approach, often categorized under CRISPR interference (CRISPRi), allows for precise, sequence-specific gene silencing without altering the underlying DNA sequence. It is primarily used in preclinical research to study gene function and is being explored for potential therapeutic applications in diseases driven by gene overexpression, such as certain cancers and neurological disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dCas9-HDAC2.